ESG

Creekstone Energy plans to add 2 gigawatts of nuclear power to its Utah Gigasite, a bold move to satisfy AI's insatiable energy appetite.

Bunker Hill Mining is pairing a strategic land grab with AI-driven exploration, a dual-pronged strategy aiming to revitalize a legendary American mining district.

With over 123 million displaced, refugee camps are now de facto cities. Temporary water solutions are fueling disease, making the case for permanent fixes.

The restaurant giant unveils a massive capital return plan, promising 100% of future free cash flow to investors while funding aggressive expansion in China.

atNorth's award-winning ICE03 facility isn't just a data center; it's a holistic model integrating green tech, circular economies, and community growth.

As Uxin prepares to report Q3 results, all eyes are on its ambitious superstore strategy and whether it can drive profitability in a complex market.

Genmab's $8 billion acquisition of Merus isn't just a deal; it's a bold strategy to own its destiny and dominate the future of oncology therapeutics.

SEALSQ appoints public-private partnership veteran Rolf Gobet to lead its new Geneva Quantum Center, a key move in a well-funded race against quantum threats.

A new startup is betting a premium AI desktop calendar can cure our smartphone addiction. But is another screen really the answer to too much screen time?

A South Korean firm has solved a hidden flaw in industrial magnets, promising a leap in efficiency for battery, recycling, and mining industries.

A new 'inspired by' fragrance brand is betting its vertically integrated model and aggressive pricing can break the industry’s century-old luxury spell.

Health Union's new platform for ATTR amyloidosis isn't just a website. It's a strategic blend of patient support and business innovation. Here's why.

Serina Therapeutics poaches a top chemist to expand its POZ platform, signaling a major push beyond Parkinson's into new, high-value drug markets.

Dialed Moods' new sea moss and shilajit gummies enter a booming market. But do the ancient ingredients and modern science justify the industry's latest rush?

Zoetis boosts its dividend by 6%, but what does this move signal about the company's financial health and the booming global animal care market?

Tenaya Therapeutics unveils promising interim data for its ARVC gene therapy, TN-401, hinting at a potential cure and igniting investor interest.

BrightView Holdings declared its eighth straight cash dividend, a move signaling financial discipline even as it navigates revenue challenges and stock volatility.

Tenaya Therapeutics seeks fresh capital to advance its heart disease pipeline, but the offering's structure raises dilution questions for investors.

Dynex's routine dividend declaration reveals a complex strategy of risk management and capital allocation, offering a masterclass in navigating mREIT turbulence.

A routine filing reveals a major strategic play. See how BridgeBio Oncology uses special equity grants to attract top minds in the fierce race for a cancer cure.